IFP Advisors
NRIX icon

IFP Advisors’s Nurix Therapeutics NRIX Stock Holding History

IFP Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.31K Hold
224
– – ﹤0.01% 3779
2026
Q2 		$5.43K Buy
+224
New +$3.82K ﹤0.01% 3741
2025
Q2 		– Hold
0
– – – 4502
2025
Q1 		– Sell
-6
Closed -$113 – 4537
2024
Q4 		$113 Buy
+6
New +$138 ﹤0.01% 3983

Other funds holding NRIX

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
WestHill Financial Advisors
WestHill Financial Advisors San Rafael, California $597M AUM 13.09% 1-Year Est. Return
Vienna Insurance Group
Vienna Insurance Group Warsaw, Poland $466M AUM 97.31% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

IFP Advisors's NRIX Position: Q3 2026 in Review

IFP Advisors held its Nurix Therapeutics (NRIX) position steady in Q3 2026 at 224 shares worth $5.31K. The position accounts for ﹤0.01% of the portfolio, ranked #3779.

IFP Advisors first reported a position in NRIX in Q4 2024 and has held it in 3 quarters since. The position peaked at $5.43K in Q2 2026. 59 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • IFP Advisors held 224 shares of Nurix Therapeutics worth $5.31K as of Q3 2026.
  • IFP Advisors left its Nurix Therapeutics share count unchanged in Q3 2026.
  • Nurix Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #3779 holding.
  • IFP Advisors first reported a position in Nurix Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • IFP Advisors's Nurix Therapeutics position peaked at $5.43K in Q2 2026.
  • 59 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.